Dr. Creager Joins Seraph’s Board of Directors

Dr. Creager Joins Seraph’s Board of Directors

Dr. Richard S. Creager

DETROIT, June 11, 2021 – Dr. Richard S. Creager, an established executive and consultant in the In Vitro Diagnostics (IVD) industry, joined Seraph’s Board of Directors this past spring.

Upon receiving his PhD in Microbiology from the University of Pittsburgh School of Medicine, Dr. Creager witnessed the dawn of the biotechnology revolution catalyzed by the development of monoclonal antibodies and PCR technology. These scientific breakthroughs encouraged him to leverage his training as a virologist to create novel diagnostic products in the private sector. 

Dr. Creager started his career working for a startup company that developed in vitro diagnostic products using DNA technology and monoclonal antibodies. He then joined Kallestad Diagnostics, which subsequently was acquired by Sanofi Diagnostics Pasteur, where he led the development of the Access Immunoassay System. After that business was sold to Beckman Coulter, he became Group Vice President of Immunoassay.  Subsequently, he became the SVP Molecular Diagnostics and Chief Science Officer for Beckman Coulter.  Dr. Creager led the development and commercialization of more than 160 IVD products for infectious disease, cardiovascular disease, fertility, thyroid disease, autoimmune disease, cancer, and women’s health. Some of the innovative products that were commercialized under his leadership include  Troponin I for the diagnosis of acute myocardial infarction, AMH, for the assessment of ovarian reserve, and the Prostate Health Index (PHI), a test used intended to reduce the number of unnecessary prostate biopsies in PSA-tested men.

While Dr. Creager recognizes the importance of innovation, he believes “Innovation alone does not determine the success of a company.” Rather, “you need to constantly talk to customers, identify their pain points, and provide tangible benefits to sustain growth”. He believes Seraph possesses these characteristics, which encouraged him to join the Board. “Seraspec is a reagentless technology delivering fast turnaround results. This is truly an innovative technology with wide utility in meeting customer needs across multiple life science and diagnostic disciplines.”  Welcome, Dr. Creager!

About Seraph Biosciences, Inc.

Incorporated in 2016, Seraph Biosciences Inc. is a biotechnology company dedicated to commercializing Seraspec® – a fully automated pathogen identification platform capable of delivering near real-time pathogen detection. Based in Detroit, Michigan, Seraph’s mission is to provide disruptive biomedical solutions to front-line providers and their patients at the point of care.